“We cannot leave the discovery of antivirals to the private sector – there is not incentive for a company to invest in a disease that might never exist. Nor can we leave to any one sector, institution or country. The needs are too great.
A new model is required. To this end, we have created a new Canadian non-profit, the Viral Interruption Medicines Initiative (VIMI)™, to retool the drug discovery and development process and rapidly develop new antiviral medicines for the future, as a public good. Accelerated by open science, and working with its international partner READDI™, VIMI™ will develop multiple “on the shelf” medicines poised to be used at the first sign of an outbreak, so that we can put out the fire before it turns into the next global health pandemic….”